Delving into the Latest Updates on Beijing Shen Aoji Medicine Science & Technology Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Neoplasms

Herbal medicine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Herbal medicine	1

Top 5 Target	Count

ERα(Estrogen receptor alpha)	1

This study aims to evaluate the material balance, metabolic transformation pathways and pharmacokinetics of [14C] arcollidine after a single oral dose in healthy Chinese male volunteers, reveal the overall pharmacokinetic characteristics of arcollidine in humans, and provide a reference for the rational use of the drug.

Start Date23 Sep 2017

Sponsor / Collaborator

Beijing Shen Aoji Medicine Science & Technology Co., Ltd.

NCT03236649 / TerminatedPhase 3

Comparison of Efficacy and Safety of Icaritin Versus Sorafenib in First-line Treatment of PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Opened Phase III Clinical Trial

The primary efficacy index of this study is to compare the OS of the two groups.

Start Date20 Sep 2017

Sponsor / Collaborator

Beijing Shen Aoji Medicine Science & Technology Co., Ltd.

[+22]

CTR20170668 / RecruitingPhase 3

阿可拉定对比索拉非尼一线治疗PD-L1阳性晚期肝细胞癌受试者的有效性与安全性的多中心随机开放性Ⅲ期临床试验

[Translation] A multicenter, randomized, open-label phase III clinical trial of the efficacy and safety of accolade versus sorafenib as first-line treatment for subjects with PD-L1-positive advanced hepatocellular carcinoma

比较两组的总生存期(OS)；比较两组的疾病进展时间(TTP)、无进展生存期(PFS)、客观缓解率(ORR)和疾病控制率(DCR)；比较两组的安全性与耐受性；

[Translation]

To compare the overall survival (OS) between the two groups; To compare the time to disease progression (TTP), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) between the two groups; To compare the safety and tolerability between the two groups;

Start Date08 Sep 2017

Sponsor / Collaborator

Beijing Shen Aoji Medicine Science & Technology Co., Ltd.

100 Clinical Results associated with Beijing Shen Aoji Medicine Science & Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Shen Aoji Medicine Science & Technology Co., Ltd.

Login to view more data

8

Literatures (Medical) associated with Beijing Shen Aoji Medicine Science & Technology Co., Ltd.

01 Jun 2018·SteroidsQ4 · MEDICINE

The ER-α36/EGFR signaling loop promotes growth of hepatocellular carcinoma cells

Q4 · MEDICINE

Article

Author: You, Hui ; Meng, Kun ; Wang, Zhao-Yi

Hepatocellular carcinoma (HCC) is the common primary liver cancer and the third leading cause of cancer related mortality worldwide. It is generally thought that the estrogen-signaling pathway is not related to the development and progression of human HCC. However, accumulating evidences indicate the existence of a rapid estrogen signaling in HCC cells that is able to promote cell growth. However, the receptor that mediates the rapid estrogen signaling in HCC cells has not been established. Previously, our laboratory identified a variant of ER-α, ER-α36, and found that ER-α36 mediates the rapid estrogen signaling such as the activation of the MAPK/ERK signaling in breast carcinoma cells. Our current experiments studied the role of the rapid estrogen signaling mediated by ER-α36 in growth of HCC HepG2 and PLC/PRF/5 cells that highly express ER-α36 and found these cells were strongly responsive to the rapid estrogen signaling. Knockdown of ER-α36 expression in these HCC cells using the shRNA method attenuated their responsiveness to estrogen and destabilized EGFR protein. ER-α36 mediated estrogen-induced phosphorylation of Src and the MAPK/ERK as well as cyclin D1 expression. In addition, there existed an ER-α36/EGFR positive regulatory loop in HCC cells that was important for the maintenance and positive regulation of HCC tumorsphere cells. Our results thus indicated that the rapid estrogen receptor is mediated by ER-α36 in HCC cells through the EGFR/Src/ERK signaling pathway and suggested that the ER-α36/EGFR signaling loop is a potential target to develop novel therapeutic approaches for HCC treatment.

20 May 2018·Journal of Clinical Oncology

A multicenter, single arm phase II trial of a small molecule immune-modulator icaritin: Safety, overall survival, immune dynamics, and PD-L1 expression in advanced hepatocellular carcinoma.

Author: Li, Shu ; Xu, Jian-Ming ; Li, Qing ; Qin, Shukui ; Meng, Kun ; Liang, Jun ; Zheng, Limin ; Ye, Bin ; Sun, Yan ; Cheng, Ying

4077Background: HCC was characterized with high heterogeneity and immune “tolerogenic”. Despite of immune checkpoint inhibitors have demonstrated promising results with improved overall survival, a...

01 May 2018·Journal of Pharmaceutical and Biomedical AnalysisQ3 · MEDICINE

Application of ultra high-performance liquid chromatography tandem mass spectrometry to investigate the regioselective glucuronidation of icaritin in vitro

Q3 · MEDICINE

Article

Author: Wu, Zhuona ; Zhu, Xiaoxia ; Li, Jian ; Meng, Zhiyun ; Liu, Taoyun ; Gan, Hui ; Peng, Jian ; Wang, Xinyu ; Sun, Wenzhong ; Jin, Mingji ; Zheng, Ying ; Dou, Guifang ; Rong, Yi ; Gu, Ruolan

Icaritin is one of the Epimedium products with various biological activities. In the present study, we developed a rapid, reliable and robust UHPLC-MS/MS method to simultaneously determine unconjugated icaritin and its multiple glucuronides (icaritin-3-glucuronide, icaritin-7-glucuronide and icaritin-3,7-diglucuronide) in microsomal incubation systems, and applied it to study icaritin regioselective glucuronidation in vitro. We identified the involvement of human UDP-glucuronosyltransferase (UGT) isoforms in icaritin metabolism and further studied the kinetic profiles of icaritin glucuronidation using pooled human liver microsomes (HLMs), pooled rat liver microsomes (RLMs), pooled human intestine microsomes (HIMs) and UGTs, respectively. We also evaluated regioselective glucuronidation of icaritin by UGT isoforms and conducted time-dependent experiment to elucidate the metabolic pathways for icaritin clearance. Catalytic efficiency of microsomes is determined according to rank orders of total intrinsic clearance (CL_int): CL_int,HLM (24.19 mL/mg/min) > CL_int,RLM (13.15 mL/mg/min) > CL_int,HIM (6.43 mL/mg/min). Besides, icaritin glucuronidation is mediated by multiple enzymes, with UGT1A1 the principal metabolizing enzyme (total CL_int,UGT1A1 = 6.38 mL/mg/min). As for the regioselectivity, except for UGT1A8 and UGT2B7, most UGT isoforms exhibit preference for the position of 3-OH on icaritin structure. Moreover, time-dependent conversion from monoglucuronides to diglucuronide indicate that icaritin-3,7-diglucuronide may be the final metabolite from icaritin elimination.

100 Deals associated with Beijing Shen Aoji Medicine Science & Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Shen Aoji Medicine Science & Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data